TP53 and PTEN as driver mutations in Zenker's carcinoma—a clinical presentation
Abstract Zenker carcinoma is still being treated empirically because of the lack of evidence‐ based guidelines. We report for the first time about the genetic examination of this rare entity. The revealed mutations show genetic similarities with HPV(‐)HNSCC which suggests that well‐known therapeutic...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.3169 |
Summary: | Abstract Zenker carcinoma is still being treated empirically because of the lack of evidence‐ based guidelines. We report for the first time about the genetic examination of this rare entity. The revealed mutations show genetic similarities with HPV(‐)HNSCC which suggests that well‐known therapeutic strategies may be applicable for this disease |
---|---|
ISSN: | 2050-0904 |